Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
Cryotherapeutics from Ans, company number BE0713882584, closed financial year 2025 with a result of € -2.3 million after tax. For that financial year Cryotherapeutics recorded a gross margin of € -29,208 and equity of € 21.1 million. Compared with financial year 2024, the result moved from € -2 million to € -2.3 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 1, 2026.
€ 21.1 million
▼ 10% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2.3 million
▼ 15 % more loss than in 2024
Profit after tax over the fiscal year.
€ 2.8 million
▼ 12% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -11 million.
People and assets in 2025
10.7
▲ 0.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.1 million
▲ 10% vs 2024
€ 103,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 38,893
▲ 85% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 424,327
▼ 20% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 181,240
▼ 22% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -217,944 | € 188,462 | € 23,850 | € -29,208 | ▼ € 53,058 |
| Profit after taxes | € -1,694,220 | € -1,815,782 | € -1,971,359 | € -2,258,299 | ▼ € 286,939 |
| Equity | € 19,794,989 | € 17,979,208 | € 23,345,446 | € 21,087,147 | ▼ 10% |
| Total debts | € 1,567,012 | € 2,069,321 | € 1,415,487 | € 693,714 | ▼ 51% |
| Cash | € 3,163,924 | € 1,406,551 | € 3,180,816 | € 2,784,170 | ▼ 12% |
| Retained profit | € -4,986,676 | € -6,802,458 | € -8,773,817 | € -11,032,116 | ▼ € 2.3 million |
| Bank debt | € 300,000 | € 300,000 | € 0 | € 0 | |
| Balance sheet total | € 21,362,002 | € 20,048,529 | € 24,760,933 | € 21,780,861 | ▼ 12% |
| Employees (FTE) | 5.4 | 7.9 | 10 | 10.7 | ▲ 0.7 |
By gross margin, Cryotherapeutics ranks 64th of 71 companies with main activity “Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied” in the province of Liège that publish figures (fiscal year 2025).
Key figures of Cryotherapeutics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about Cryotherapeutics the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Cryotherapeutics?
What happened at Cryotherapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Yiannakis YIANNI stepped down as director. NBB
- NOSHAQ Partners SCRL stepped down as director. NBB
- NRW BANK stepped down as director. NBB
- Chen Yen-Fu stepped down as director. NBB
- Peppermint Venture Partners GMBH stepped down as director. NBB
- Christine RAINER stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2.3 million. Source: NBB ↗
- Yiannakis YIANNI became a director. NBB
In short
From € 1.7 million loss in 2022 to € 2.3 million loss in 2025.
On average € 2,400 of value added per employee in 2024.
Management
It owns 100% of Cryotherapeutics GmbH itself.
Directors
According to the 2025 annual accounts
Yiannakis YIANNI
Managing director
since 2025 · until 2028
Director · represented by Eric BRANDT
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE, SOGECOM, VITAVERDE.BIO, HAEMERS Technologies, SPACEBEL, NOSHAQ VENTURE +168 more
since 2025 · until 2028
NRW BANK
Director · represented by Florian STINAUER
since 2025 · until 2028
Chen Yen-Fu
Director
since 2025 · until 2028
Peppermint Venture Partners GMBH
Director · represented by Joachim RAUTTER
since 2025 · until 2028
Christine RAINER
Director
since 2025 · until 2028
Establishments
Establishment units
Physical locations of this company
Avenue Alfred Deponthière 46 box 21
4431 Ans
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in the province of Liège
Same main activity (Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied), 89 active companies in the province of Liège, largest first.
STERIGENICS BELGIUM (Petit Rechain)
€ 44.1 million revenue · 2025 · Verviers
€ 21 million revenue · 2025 · Liège
MITHRA Recherche et Développement
€ 17.7 million revenue · 2022 · Liège
Advanced Coatings & Construction Solutions
€ 17.1 million revenue · 2025 · Liège
€ 12.5 million revenue · 2025 · Seraing
€ 8 million gross margin · 2025 · Herstal
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
CLOUDFLARESPECTRUM Cloudflare, Inc., US
DNS
OVH DNS
Domain
Domain
cryotherapeutics.com
Registered
2005-03-01
Registrar
OVH sas
Expires
2027-03-01
Website info
Features
Security
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Capital increase
Source: Deed ↗- NOSHAQ EUROPE 3 SA(inbrenger van schuldvordering (apport en nature)) 0.9%
Incorporation
Source: Deed ↗- Cryotherapeutics GmbH(oprichter, intekenaar) 99.9%
- YIANNI Yiannakis Petrou(oprichter, simple souscripteur) 0.1%
Details
- Company number
- 0713.882.584
- VAT number
- BE 0713.882.584
- Registered office
- Avenue Alfred Deponthière 46 bus 21, 4431 Ans
- Names & denominations
- Cryotherapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 26 November 2018
- Peppol
- Active · Active since 16 Sept 2025
- Contact
- cryotherapeutics.com
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Vervaardiging van overige farmaceutische producten
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Detailhandel in farmaceutische producten